What Is Selank?
Selank is a synthetic heptapeptide developed in Russia by the Institute of Molecular Genetics of the Russian Academy of Sciences. It was designed as a stable analogue of tuftsin, a naturally occurring tetrapeptide produced by the spleen that plays a role in immune regulation. By extending the tuftsin sequence and modifying its structure, researchers created a compound with significantly greater metabolic stability and a distinct psychopharmacological profile.
Selank was developed from tuftsin for central nervous system research. Much of the available literature concerns intranasal study formulations; that does not establish the safety or effects of other formulations or routes.
Selank has been approved in Russia as an anxiolytic and nootropic agent under the trade name Selank, and it has been in clinical use there since the mid-2000s. Outside of Russia, it remains a research compound with no approved therapeutic status in the EU, UK, or United States.
How does it work?
Selank appears to work through several overlapping pathways, which may explain why its profile differs from conventional anxiety medications.
The most studied mechanism involves modulation of the GABAergic system — the brain's primary inhibitory signalling network. GABA (gamma-aminobutyric acid) is the neurotransmitter that reduces neuronal excitability, producing calming effects. Classic anxiolytic drugs such as benzodiazepines work by amplifying GABA signalling at the GABA-A receptor. Selank appears to influence GABAergic tone, but through a modulatory rather than direct agonist mechanism. This distinction is considered significant in the research literature because direct GABA-A agonism is associated with tolerance, physical dependence, and withdrawal — effects that have not been observed with Selank in the published studies to date.
Beyond GABAergic effects, Selank has been shown in animal and in vitro studies to increase the expression of brain-derived neurotrophic factor (BDNF), a protein that supports the growth, survival, and differentiation of neurons. BDNF is strongly associated with learning, memory consolidation, and stress resilience. Low BDNF levels are observed in conditions including depression and chronic stress disorders. The upregulation of BDNF by Selank is one of the proposed explanations for its reported cognitive effects.
Selank also appears to influence serotonin metabolism, increasing the activity of serotonin-degrading enzymes and modulating serotonin availability in ways that may contribute to mood stabilisation. There is also evidence of interaction with the opioid and dopamine systems, though these pathways are less thoroughly characterised.
Finally, given its origins as a tuftsin analogue, Selank retains some immunomodulatory properties, with research indicating effects on interleukin expression and immune cell activity — though the relevance of this to its anxiety-reducing profile in humans remains unclear.
What Does the Research Say?
The body of research on Selank is real but limited in scope and predominantly Russian-language, which creates a significant access and verification challenge for researchers outside Russia.
The most cited human clinical evidence comes from Russian trials conducted in the late 1990s and 2000s, involving patients with generalised anxiety disorder (GAD). One series of studies reported that intranasal Selank produced anxiolytic effects comparable to medazepam (a benzodiazepine) over a treatment period of 10–14 days, without the sedation, cognitive blunting, or dependency risk associated with benzodiazepines. Participants in these trials reportedly showed improvements on standardised anxiety rating scales. However, many of these studies were conducted in relatively small cohorts, and the trial methodology has not been independently replicated in peer-reviewed Western clinical settings.
In animal models, the evidence is broader. Rodent studies have demonstrated dose-dependent reductions in anxiety behaviour on elevated plus-maze and open-field tests. BDNF upregulation has been documented in rat brain tissue following Selank administration. Cognitive performance under stress conditions — tasks requiring sustained attention and working memory — has also been shown to improve in animal studies. Importantly, these studies consistently note an absence of sedation at anxiolytic doses, which distinguishes Selank from most classical anxiolytics in animal testing.
Research into Selank's nootropic properties, meaning its potential to enhance cognitive function beyond simply reducing anxiety, is a smaller but growing area. Some studies suggest improved learning and memory consolidation in animal models, with BDNF induction proposed as a likely mediator. A 2014 study published in the journal Molecular Biology examined gene expression changes following Selank administration and found modulation of several genes involved in synaptic plasticity and neuroprotection.
The honest summary for researchers is this: the compound has a plausible mechanism, consistent animal data, and early-stage human evidence supporting its anxiolytic profile — but the clinical evidence base is shallow by Western pharmaceutical standards, with limited independent replication, small sample sizes, and a concentration of primary research in one country's scientific infrastructure. The English-language literature remains sparse, and peer review of the Russian clinical trials by international bodies has not been systematic.
What does this mean in Ireland?
Selank is not an authorised medicine in Ireland. Advertising unauthorised human medicines is prohibited; supply and import are subject to legal restrictions. Check current HPRA and Revenue guidance.
A research label or certificate of analysis does not establish safety for people or medicine authorisation.
The short version
- Selank is a synthetic analogue of the immune peptide tuftsin, developed in Russia and approved there as an anxiolytic and nootropic agent.
- Study formulations and routes differ; findings about one formulation do not establish the safety or effects of another.
- Its proposed mechanisms include GABAergic modulation, BDNF upregulation, and serotonin system interaction — without the direct GABA-A agonism associated with benzodiazepine dependency.
- Russian clinical trials suggest anxiolytic effects comparable to benzodiazepines, without sedation or dependency, but independent replication in Western clinical trials is limited.
- Animal data is more consistent: multiple rodent studies report reduced anxiety behaviour, cognitive protection under stress and increased BDNF.
- The English-language evidence base is sparse, and researchers should weigh this alongside the positive signals in the available literature.
- Selank is not an authorised medicine in Ireland.
- For those tracking developments in peptide research, Selank's mechanism and early clinical profile make it a compound worth following as the evidence base matures.